Abby Hardy, Author at BioTuesdays

Developments

FDA approves Chembio’s dual path platform HIV-syphilis testing system

The FDA approved Chembio Diagnostics’ (NASDAQ:CEMI) dual path platform (DPP) HIV-syphilis system, a 15-minute test designed to detect HIV Type 1 and 2 antibodies and the bacteria that causes syphilis. The system...

October 2, 2020

Developments

Synthetic Biologics discontinues Phase 2b irritable bowel syndrome trial

Synthetic Biologics (NYSE American:SYN) reported disappointing results from an interim futility analysis of its Phase 2b clinical study of SYN-010 for the treatment of irritable bowel syndrome with constipation. While...

October 2, 2020

Developments

Otonomy completes enrollment in Phase 3 Meniere’s disease trial

Otonomy (NASDAQ:OTIC) completed enrollment in its Phase 3 study evaluating OTIVIDEX for the treatment of Meniere’s disease, a disorder of the inner ear that can lead to vertigo and hearing loss. The trial enrolled 149...

October 2, 2020

Developments

Windtree doses first patient in Phase 2 cardiogenic shock study

Windtree Therapeutics (NASDAQCM:WINT) dosed the first patient in its Phase 2 study evaluating istaroxime in patients with early cardiogenic shock due to heart failure. Cardiogenic shock is a condition where the heart...

October 1, 2020

Developments

Athira initiates dosing in Phase 2/3 Alzheimer’s disease study

Athira Pharma (NASDAQ:ATHA) initiated patient dosing in its Phase 2/3 trial evaluating ATH-1017 for the treatment of mild-to-moderate Alzheimer’s disease. ATH-1017 is a small molecule designed to regenerate brain...

October 1, 2020

Executive Moves

Kaleido Biosciences names Daniel Menichella as president and CEO

Daniel Menichella Kaleido Biosciences (NASDAQ:KLDO) appointed Daniel Menichella as president and CEO, effective Oct. 13. Mr. Menichella will replace Alison Lawton, who is stepping down for personal reasons...

October 1, 2020

Developments

Clarigent Health launches Clairity suicide risk identification app

Closely-held Clarigent Health launched Clairity, an app-based listening tool designed to provide clinical decision support to mental health professionals. Clairity uses AI to analyze speech and identify vocal...

October 1, 2020

Developments

Soleno Therapeutics updates topline data from Phase 3 Prader-Willi Syndrome trial

Soleno Therapeutics (NASDAQ:SLNO) updated topline results from its Phase 3 trial evaluating diazoxide choline controlled-release (DCCR) tablets for the treatment of Prader-Willi Syndrome (PWS). The randomized, double...

September 30, 2020

Developments

Ocular Therapeutix doses first patients in Phase 2 dry eye disease trial

Ocular Therapeutix (NASDAQ:OCUL) dosed the first patients in its Phase 2 trial evaluating OTX-CSI for the treatment of dry eye disease. The trial will enroll some 105 patients who will receive either one of two...

September 29, 2020

Developments

Forte Biosciences doses first patient in Phase 2 atopic dermatitis trial

Forte Biosciences (NASDAQ:FBRX) dosed the first patient in its Phase 2 trial evaluating FB-401 for the treatment of atopic dermatitis. FB-401 is a topical mixture comprised primarily of three strains of the commensal...

September 29, 2020

Author - Abby Hardy

FDA approves Chembio’s dual path platform HIV-syphilis testing system

Synthetic Biologics discontinues Phase 2b irritable bowel syndrome trial

Otonomy completes enrollment in Phase 3 Meniere’s disease trial

Windtree doses first patient in Phase 2 cardiogenic shock study

Athira initiates dosing in Phase 2/3 Alzheimer’s disease study

Kaleido Biosciences names Daniel Menichella as president and CEO

Clarigent Health launches Clairity suicide risk identification app

Soleno Therapeutics updates topline data from Phase 3 Prader-Willi Syndrome trial

Ocular Therapeutix doses first patients in Phase 2 dry eye disease trial

Forte Biosciences doses first patient in Phase 2 atopic dermatitis trial

General

More